Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

GOMEKLI

MIRDAMETINIB

Standard Dose
1MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview GOMEKLI is listed in Drugs@FDA under application 219379 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient MIRDAMETINIB Form and strength TABLET, FOR SUSPENSION;ORAL - 1MG Sponsor SPRINGWORKS Submission history Latest submission status date: 2025-02-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview GOMEKLI is listed in Drugs@FDA under application 219379 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient MIRDAMETINIB Form and strength TABLET, FOR SUSPENSION;ORAL - 1MG Sponsor SPRINGWORKS Submission history Latest submission status date: 2025-02-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.